Based on the Rigel Pharmaceuticals Inc stock forecast from 5 analysts, the average analyst target price for Rigel Pharmaceuticals Inc is USD 31.50 over the next 12 months. Rigel Pharmaceuticals Inc’s average analyst rating is Buy . Stock Target Advisor’s own stock analysis of Rigel Pharmaceuticals Inc is Slightly Bearish, which is based on 4 positive signals and 5 negative signals. At the last closing, Rigel Pharmaceuticals Inc’s stock price was USD 17.09. Rigel Pharmaceuticals Inc’s stock price has changed by +1.61% over the past week, -32.85% over the past month and +23.84% over the last year.
No recent analyst target price found for Rigel Pharmaceuticals Inc
No recent average analyst rating found for Rigel Pharmaceuticals Inc
Company Overview Rigel Pharmaceuticals Inc
Rigel Pharmaceuticals, Inc., a biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer. The company's commercialized products include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; Rezlidhia, a non-intensive monotherapy for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer, as well as for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer. It also develops R289, an oral IRAK1/4 Inhibitor, which is in Phase 1b clinical trials for the treatment of hematology-oncology, autoimmune, and inflammatory diseases; and a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor program in clinical development with partner Eli Lilly and Company. In addition, the company has product candidates in clinical development with partners BerGenBio ASA and Daiichi Sankyo. The company has strategic development collaboration with The University of Texas MD Anderson Cancer Center for the development of REZLIDHIA (Olutasidenib) in acute myeloid leukemia (AML) and other hematologic cancers. The company was incorporated in 1996 and is headquartered in South San Francisco, California. Read Less
Rigel Pharmaceuticals, Inc., a biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer. The company's commercialized products include Tavalisse, an oral spleen tyrosine kinase inhi...Read More
Frequently Asked Questions About Rigel Pharmaceuticals Inc (RIGL) Stock
Based on ratings from 5 analysts Rigel Pharmaceuticals Inc's stock is Buy . Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has 2 buy, sell and 4 hold ratings.
Unfortunately we do not have enough data on RIGL's stock to indicate if its a good dividend stock.
Based on targets from 5 analysts, the average taret price for RIGL is USD 31.50 over the next 12 months. The maximum analyst target price is USD 57 while the minimum anlayst target price is USD 15.
RIGL stock's Price/Earning ratio is 64.37.
Our analysis grades RIGL stock's Price / Earning ratio at F. This means that RIGL stock's Price/Earning ratio is above 86% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this RIGL may be a overvalued for its sector.
The last closing price of RIGL's stock was USD 17.09.
The most recent market capitalization for RIGL is USD 0.31B.
Based on targets from 5 analysts, the average taret price for RIGL is projected at USD 31.50 over the next 12 months.
This means that RIGL's stock price may go up by +84.32% over the next 12 months.
We can't find any ETFs which contains Rigel Pharmaceuticals Inc's stock.
As per our most recent records Rigel Pharmaceuticals Inc has 147 Employees.
Rigel Pharmaceuticals Inc's registered address is 611 Gateway Blvd, South San Francisco, CA, United States, 94080.
You can get more information about it from Rigel Pharmaceuticals Inc's website at https://www.rigel.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior return on assets
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
Superior Earnings Growth
This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.
High Gross Profit to Asset Ratio
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About Rigel Pharmaceuticals Inc (RIGL) Stock
Based on ratings from 5 analysts Rigel Pharmaceuticals Inc's stock is Buy . Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has 2 buy, sell and 4 hold ratings.
Unfortunately we do not have enough data on RIGL's stock to indicate if its a good dividend stock.
Based on targets from 5 analysts, the average taret price for RIGL is USD 31.50 over the next 12 months. The maximum analyst target price is USD 57 while the minimum anlayst target price is USD 15.
RIGL stock's Price/Earning ratio is 64.37.
Our analysis grades RIGL stock's Price / Earning ratio at F. This means that RIGL stock's Price/Earning ratio is above 86% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this RIGL may be a overvalued for its sector.
The last closing price of RIGL's stock was USD 17.09.
The most recent market capitalization for RIGL is USD 0.31B.
Based on targets from 5 analysts, the average taret price for RIGL is projected at USD 31.50 over the next 12 months.
This means that RIGL's stock price may go up by +84.32% over the next 12 months.
We can't find any ETFs which contains Rigel Pharmaceuticals Inc's stock.
As per our most recent records Rigel Pharmaceuticals Inc has 147 Employees.
Rigel Pharmaceuticals Inc's registered address is 611 Gateway Blvd, South San Francisco, CA, United States, 94080.
You can get more information about it from Rigel Pharmaceuticals Inc's website at https://www.rigel.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for RIGL !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
